Table 1.

Testing brain biomarkers after mTBI in patients on oral anticoagulants. S100B: calcium-binding protein B; NSE: neuron-specific enolase; UCHL1: ubiquitin carboxyl-terminal hydrolase isozyme L1; GFAP: glial fibrillary acidic protein.

Biomarker	Study	Patients on OAT Included	Analysis of the Patients on OAT	Results	Reference
S100B	Biberthaler et al. 2006	0/1309	No	/	[47]
	Laribi et al. 2014	0/431	No	/	[48]
	Morochovič et al. 2009	0/102	No	/	[49]
	David et al. 2017	83/308	No	NPV 94.3% (95% CI: 87.2–98.1%) PPV 12.7% (95% CI: 8.6–17.9%)	[54]
	Menditto et al.	313/313	Yes	NPV 86.9% (95% CI: 82.5–90.3%) PPV 15.9% (95% CI: 12.1–20.5%)	[55]
NSE	Menditto et al.	313/313	Yes	NPV 84.3% (95% CI: 79.7–88.1%) PPV 13.0% (95% CI: 9.6–17.4%)	[55]
UCHL1	Menditto et al.	313/313	Yes	NPV 88.1% (95% CI: 82.8–91.9%) PPV 17.3% (95% CI: 12.6–23.1%)	[55]
GFAP	Menditto et al.	313/313	Yes	NPV 95.8% (95% CI: 92.0–97.9%) PPV 16.6% (95% CI: 12.0–22.4%)	[55]